WHO IS Ypsomed by mylife: In 1984, Disetronic was founded by the brothers Willy and Peter Michel, in Burgdorf, Switzerland. The successful company was the first one to introduce a micro insulin pump on the market. Besides its infusion systems, Disetronic specialised in injection systems. In 2003, the co-founder and main shareholder, Willy Michel, sold Disetronic with its infusion business to Roche. However, he kept the injection business. That is how Ypsomed was born. Ever since, Ypsomed has written its own success story. On 22 September 2004, Ypsomed got listed on SIX Swiss Exchange. Meanwhile, Ypsomed is back in the insulin pump business: from 2010 to 2018 as a distributor of the mylife OmniPod by Insulet and since 2016 with its own insulin pump, the mylife YpsoPump.
Ypsomed partners with Dexcom, promises future closed loop using TypeZero algorithm was announced by Eli Lilly, 19 November 2020.
Eli Lilly and Company and Ypsomed announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly’s connected diabetes solutions. Under the terms of the agreement, Lilly will commercialize the system, which is currently in development and will include an insulin pump developed and manufactured by Ypsomed.
Ypsomed’s insulin pump has been marketed in Europe since 2016. Available in 21 countries as the mylife™ YpsoPump®, this pump stands out for its small size and its unique, icon-based touch screen. Lilly will commercialize a version of this insulin pump, along with continuous glucose monitoring (CGM) and automated insulin delivery technology, in the United States and Europe. This pump will use pre-filled insulin cartridges for Lilly’s rapid-acting insulins.
Ypsomed plans to submit a version of the mylife YpsoPump for clearance to the U.S. Food and Drug Administration for use in automated insulin delivery in 2022. If cleared, Lilly will have exclusive rights to commercialize the pump in the U.S.
Ypsomed partners with Dexcom, promises future closed loop using TypeZero algorithm was written by Mary Anne Patton of MyArtificialPancreas.net, 4 May 2020.
Ypsomed and Dexcom have announced their partnership, 4 May 2020 and say a future version of the Ypsomed pump will loop with the TypeZero algorithm, the algorithm used in Tandem’s Control IQ. The next version of the Ypsomed pump, which is expected to be available in the first half of 2021, will enable bolus from phone. The company says people using Ypsomed pumps will be able to automatically upgrade to the bolus from phone version of their pump, for no charge.
It’s a tiny pump with a 160 ml reservoir. This will not suit everyone, but will be great for T1Ds who use low daily doses. It will also fit into personal clothing for times the user is not wearing clothes with pockets. It has a bright screen and large icons and fonts.
Read more: Ypsomed partners with Dexcom
Sea Snail, Human Insulin Hybrid Could Lead to Better Diabetes Treatments was reported by Doug Dollemore for University of Utah Health, 1 June 2020.
Nearly a century after insulin was discovered, an international team of researchers including University of Utah Health scientists report that they have developed the world’s smallest, fully functional version of the hormone, one that combines the potency of human insulin with the fast-acting potential of a venom insulin produced by predatory cone snails. The finding, based on animal studies, could jumpstart the development of insulin treatments capable of improving the lives of those with diabetes.
“We now have the capability to create a hybrid version of insulin that works in humans and that also appears to have many of the positive attributes of cone snail insulin,” says Danny Hung-Chieh Chou, Ph.D, a U of U Health assistant professor of biochemistry and one of the study’s corresponding authors. “That’s an important step forward in our quest to make diabetes treatment safer and more effective.”
The study appears in Nature Structural and Molecular Biology.
As cone snails slither across coral reefs, they are constantly on the prowl for prey. Some of these fish-hunting species, such as Conus geographus, release plumes of toxic venom that contain a unique form of insulin into the surrounding water. The insulin causes fish blood glucose levels to plummet, temporarily paralyzing them. As the fish flounders, the snail emerges from its shell to swallow the subdued victim whole.
Faster-acting insulin would diminish the risk of hyperglycemia and other serious complications of diabetes, says Helena Safavi, Ph.D., a study co-author and an assistant professor of biomedical sciences at the University of Copenhagen in Denmark. It also could improve the performance of insulin pumps or artificial pancreas devices, which automatically release insulin into the body as needed. “We want to help people with diabetes to more tightly and rapidly control their blood sugar,” she says
Note of caution before you get excited, from a local beta cell researcher: “There have been over 375 technologies that have worked in mice that have failed to move forward. I hope it works this time.”
Cure for diabetes? University of Alberta researchers believe they’ve found one, as reported by Jay Rosove, for CTVNews.ca, 17 November 2020
Scientists at the University of Alberta say they may have discovered a cure for diabetes. So far, the research team has been able to cure diabetes in mice using a new stem cell process, and is hopeful that process will translate to humans. The lead researcher on the project, Dr. James Shapiro, told CTV News Edmonton that his team at the U of A was able to collaborate with experts from around the world to turn a patient’s own blood into insulin-producing islet cells.
Twenty years ago, the same Dr. Shapiro made medical history with the “Edmonton Protocol,” a procedure that gives patients new insulin-producing cells, thanks to islet transplants from organ donors. That procedure, though, necessitates the use of powerful anti-rejection medications which carry significant side effects.
Dr. Shapiro says this new stem cell process would eliminate that problem. “If they’re their own cells, patients won’t reject them,” he said.